Biotech Stocks Worth A Glance Testing Sector Trends

CORAL SPRINGS, Florida, October 20, 2016 /PRNewswire/ --

For the most part Biotech stocks in general have performed well over the past year or so and appear to be bouncing back from a slump that began in the later part of last year. Some biotechs and pharma companies to keep a close eye on include Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Moleculin Biotech, Inc. (NASDAQ: MBRX), Amarin Corporation plc (NASDAQ: AMRN), Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) and Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP).

Moleculin Biotech, Inc. (NASDAQ: MBRX) today announced a reminder that it will host a conference call to discuss important positive developments regarding Annamycin, its drug candidate for the treatment of Acute Myeloid Leukemia, as well as to provide a general corporate update.   The call will be held today, October 20, 2016 at 5:00 pm Eastern Time and can be accessed with the following dial-in information: Participant dial in (toll free): 1-877-418-3859 - Participant international dial in: 1-412-902-6506  --  Please ask to be joined into the Moleculin call.  --  Participant Entry Number:  4494430

This conference call will be recorded and made available for replay as follows:  US Toll Free: 1-877-344-7529  --  International Toll: 1-412-317-0088 - Canada Toll Free:1-855-669-9658  --  Replay Access Code: 10095171 -- End Date: November 3, 2016  --  To access the replay using an international dial-in number, please select this link:  https://services.choruscall.com/ccforms/replay.html

Read this and details for Moleculin Biotech (MBRX) at: http://financialnewsmedia.com/profiles/mbrx.html

Moleculin Biotech announced earlier this month it has secured an agreement with Dermin Sp. Zo. O. ("Dermin") to utilize Dermin's supply of Annamycin for its upcoming clinical trial, substantially reducing the expenditures required of Moleculin for drug product and shortening the time required to produce clinical supplies.  "This was an important agreement and key milestone to be reached as it clearly shortens the pathway as well as lowers the expense involved in our clinical timeline and go to market strategy," commented Walter Klemp, Chairman and Acting CEO of Moleculin. "With this agreement in place, our drug product expense for our upcoming clinical trial will be substantially below what we had previously budgeted. Additionally, Dermin's existing supply alleviates any potential drug production constraints and advances our ability to begin our next trial expeditiously."

In other market briefings & developments in the Biotech/Pharma sectors: 

Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) this week provided an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study in patients with chronic low back pain. Fasinumab is an investigational Nerve Growth Factor (NGF) antibody in clinical development for osteoarthritis pain and chronic low back pain.  Read more at finance.yahoo.com/news/regeneron-teva-fasinumab-clinical-development-110000723.html

Amarin Corporation plc (NASDAQ: AMRN) closed up at $3.06 on over 4.66 Million shares traded by the market close on Wednesday.  Amarin last month announced that, as expected, the independent data monitoring committee (DMC) has completed its review of the first pre-specified interim efficacy analysis for the REDUCE-IT cardiovascular outcomes study and has recommended that the trial continue as planned without modification. The 8,175-patient outcomes study is evaluating whether treatment with Vascepa® (icosapent ethyl) reduces cardiovascular events in patients who despite stabilized statin therapy have elevated triglyceride levels and other cardiovascular risk factors.

Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, this week announced that the last patient has completed dosing and all monitoring visits in its Phase 2b/3 clinical trial of RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced on Tuesday of this week that the European Commission has granted Orphan Designation in the European Union for the Company's novel synthetic oral endocannabinoid-mimetic drug, Resunab, for the treatment of cystic fibrosis ("CF").

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com.  Follow us on Facebook: facebook.com/financialnewsmedia and Twitter: twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand nine hundred dollars for news coverage of the current press release issued by Moleculin Biotech, Inc. by a non-affiliated third party.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  [email protected]
Phone: +1-(954)345-0611
URL: http://www.financialnewsmedia.com
Source:  FN Media Group

SOURCE FN Media Group, LLC